Abstract
Biocryst Pharmaceuticals will post second-quarter 2026 results on August 05, 2026 Pre-Market; this preview summarizes anticipated revenue, profitability, and adjusted EPS trends, alongside segment dynamics and consensus views over the January 01, 2026 to July 29, 2026 period.
Market Forecast
Consensus for the current quarter points to revenue of 182.51 million US dollars, with estimated EBIT of 41.44 million US dollars and adjusted EPS of 0.12. Year over year, revenue is forecast to rise by 21.89%, EBIT by 65.73%, and adjusted EPS by 746.86%. Gross margin guidance was not provided in the forecast data, but the prior quarter’s baseline implies a high-50% range; net income guidance is not explicitly available, though EBIT growth implies better operating leverage.
Management’s topline story continues to hinge on product revenue expansion from its core franchises, with growth weighted to on-market therapies and supported by incremental license and collaboration income. The company’s most promising growth driver is its product revenue line, projected to remain the primary contributor; last quarter, products generated 151.40 million US dollars, while license and collaboration revenues were 3.02 million US dollars and 2.00 million US dollars, respectively.
Last Quarter Review
In the prior quarter, revenue reached 156.41 million US dollars, with a gross profit margin of 58.00%, a GAAP net loss attributable to the parent company of 722.00 million US dollars, no disclosed net profit margin figure, and adjusted EPS of -0.09; revenue grew 7.48% year over year on the finance tool’s data. GAAP net profit quarter-on-quarter momentum, reflected by a ran_on_month_change of -393.60 (interpreted as -39,360%), underscores the volatility tied to non-operating or non-cash items.
Main business performance skewed to products at 151.40 million US dollars, with small contributions from license at 3.02 million US dollars and collaboration and other at 2.00 million US dollars; the results point to continued reliance on product sales as the principal revenue stream.
Current Quarter Outlook
Main commercial franchise trajectory
Biocryst Pharmaceuticals’ revenue base remains dominated by product sales, which represented 96.80% of last quarter’s revenue. The forecasted total revenue of 182.51 million US dollars implies a meaningful sequential and year-over-year acceleration relative to the 156.41 million US dollars last quarter, signaling continued unit demand growth and maturing prescriber adoption. Operating leverage should improve alongside the forecasted EBIT increase to 41.44 million US dollars, assuming stable cost discipline around SG&A and R&D within guidance. With last quarter’s gross margin at 58.00%, incremental volume at a similar or modestly higher mix could expand operating margin, though inventory and manufacturing absorption dynamics may temper near-term upside.
Most promising growth engine
Product revenue is again the most promising segment for the current quarter. The estimated 21.89% revenue growth suggests the company is benefiting from expanding patient penetration and a more favorable payer and reimbursement environment across its core therapy areas. While license and collaboration contributions are relatively small, periodic milestone or upfront fees can create intra-quarter volatility; absent explicit guidance, our baseline view assigns limited impact from these sources in the quarter. The forecasted 65.73% EBIT growth, well ahead of revenue growth, implies margin uplift driven by operating efficiency and higher scale in the product business.
Key stock price swing factors
Profitability trajectory is central this quarter, with the step-up from negative adjusted EPS last quarter to an estimated positive 0.12 likely to be interpreted as an inflection in earnings quality and operating leverage. Investors may scrutinize the gap between EBIT and GAAP net income following last quarter’s large GAAP loss; clarity on non-cash charges, one-time items, or fair-value adjustments will be crucial for understanding durability. Revenue mix and gross margin trends will be watched closely; sustaining or improving a high-50% gross margin level would support the narrative of scalable manufacturing and pricing resilience, while any contraction could raise questions about discounting, mix, or cost inflation.
Analyst Opinions
Across recent commentary within the period, the prevailing tone is cautiously optimistic, with the majority expecting revenue and profitability to improve sequentially and year over year, anchored by growth in product sales and disciplined operating expense management. Houses expressing a constructive stance highlight the magnitude of the forecasted EPS swing from -0.09 to roughly 0.12 and the 21.89% revenue growth estimate as evidence of a strengthening earnings profile. Analysts also note that a 65.73% estimated EBIT growth rate, outpacing the top line, suggests meaningful operating leverage and potential for further upside if gross margins hold near last quarter’s 58.00% baseline.
A minority of cautious views focus on the divergence between EBIT and GAAP net income given last quarter’s 722.00 million US dollars GAAP net loss; these voices look for management to address non-cash charges and any balance-sheet related impacts that could cloud the comparability of bottom-line metrics. Nonetheless, the balance of opinions leans toward expecting a cleaner quarter with positive adjusted earnings, improved operating efficiency, and continued revenue momentum from the core product franchise, forming the basis for a cautiously optimistic consensus into August 05, 2026.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments